PURPOSE Opioid misuse in the context of chronic opioid therapy (COT) is a growing concern. Depression may be a risk factor for opioid misuse, but it has been diffi cult to tease out the contribution of co-occurring substance abuse. This study aims to examine whether there is an association between depression and opioid misuse in patients receiving COT who have no history of substance abuse.
INTRODUCTION
P rescription of opioid medications for the treatment of chronic noncancer pain has become common. Chronic opioid therapy (COT) is complicated by balancing pain relief with the risk of misuse. Prescription opioids are the fastest growing form of drug abuse and the most common cause of unintentional overdose. 1, 2 Misuse of prescribed opioids may be an important link between rising rates of opioid-related abuse and overdoses. 3, 4 The National Institute for Drug Abuse defi nes prescription opioid misuse as "taking a medication in a manner other than that prescribed or for a different condition than that for which the medication is prescribed." 5 Other defi nitions of opioid misuse exist. The addiction literature often focuses on such aberrant behavior as giving opioid medications to or getting them from others. 6, 7 In primary care settings, misuse is often defi ned as nonadherence, generally meaning taking more medication than prescribed and asking for early refi lls. 8 The National Institute for Drub Abuse defi nition also encompasses taking opioids for symptoms other than pain.
DEPR ES SION A ND OPIOID MISUSE
Depression complicates the management of chronic pain. [10] [11] [12] Research has shown that patients with depression are more likely to receive COT. 3, [13] [14] [15] [16] [17] [18] Some evidence suggests that a mental health diagnosis may be a risk factor for opioid misuse. 3, 13, 14, [19] [20] [21] [22] The association between a mental health diagnosis and opioid misuse may be due to comorbid substance use disorders (SUDs), as a history of substance abuse is the most consistent predictor of both COT use and misuse. 15, 16, 19, 20 In one study, rates of COT use for chronic noncancer pain among individuals with SUDs were 4 times higher than for those without SUDs. Patients with SUDs were also more likely to receive higher doses, more days' supply, and more-potent opioids. 23 Another study found that SUDs were associated with a 6.6 times increased rate of borrowing opioid medications and a 3.7 times increased rate of requesting early refi lls. 7 Because the risks of opioid misuse associated with SUDs are well-documented, we focused on the relationship between depression and misuse among those without SUDs.
The primary objective of this study was to better characterize the relationship between depression and self-reported opioid misuse among patients with no history of SUDs who were receiving COT for chronic noncancer pain. We examined the following misuse behaviors: (1) using opioids for stress or sleep, (2) using more opioids than prescribed and/or requesting early refi lls, and (3) sharing opioids with or receiving them from others. We hypothesized that depressed patients would be more likely to use opioids for non-pain symptoms and take more medication than prescribed. With no known SUD in this population, we suspected that there would be no association between depression and giving or getting opioids. A secondary objective of this study was to identify other clinical variables associated with misuse.
METHODS
The CONSORT study (CONsortium to Study Opioid Risks and Trends), funded by the National Institute for Drug Abuse, was initiated to study COT for chronic noncancer pain among adults. The study took place at Group Health Cooperative (GHC) in Washington State and Kaiser Permanente of Northern California (KPNC). Together, these health plans serve approximately 4 million people. The study was reviewed and approved by the Institutional Review Boards at both sites.
Inclusion and Exclusion Criteria
Data were collected during a single telephone interview of COT patients. To be eligible for the survey, GHC and KPNC members aged between 21 and 80 years must have fi lled at least 10 opioid prescriptions or received at least a 120-day supply in the year before the interview. In addition, at least 90 days must have elapsed between the fi rst and last opioid dispensing in that year. These criteria for long-term opioid use have been shown to predict a high probability of sustained opioid use 1 year later. 24 Opioid usage was ascertained through the institutions' electronic pharmacy databases, which capture 90% of prescription medications used by members. 25, 26 To tease out the contribution of depression from substance abuse, we excluded patients with a known SUD from the current analysis. Patients were excluded if they responded "yes" to the following interview question: "Have you ever had an alcohol or drug problem?" Similarly, patients were excluded if they received a diagnosis of drug or alcohol abuse or dependence in the 3 years before the interview according to automated diagnosis data.
The current analysis is restricted to those patients who reported using opioid medications in the last 2 weeks. All CONSORT patients were required to be continuously enrolled in either GHC or KPNC 1 year before sampling. Patients who received a cancer diagnosis (according to Western Washington Cancer and Surveillance Epidemiology and End Results registries), except skin cancer other than melanoma, or who had 2 or more cancer diagnoses according to the automated visit records in the year before sampling were excluded from the CONSORT study.
Sampling
Patients were selected using stratifi ed sampling, selecting equal numbers of patients within 3 dosage strata (1 to 49 mg, 50 to 99 mg, and 100 mg or more, morphine-equivalent dose). The morphine-equivalent dose for each opioid prescription was calculated by multiplying the quantity of the prescription by the strength (milligrams per unit dispensed) and then by a conversion factor. 27 Means, variances, proportions, and other estimates reported in this article were obtained using estimation methods for a stratifi ed random sample.
Telephone Survey Procedures
At GHC, interviews were conducted between June 2008 and November 2008. At KPNC, interviews were conducted from January 2009 to October 2009. A letter explaining the study was mailed to potentially eligible patients. Potential GHC respondents received a $2 bill with the letter; KPNC members received a $5 gift card for a national retail store. Potential respondents were then called by survey interviewers in the collaborating health plan research centers. Patients were asked to take part in a 30-minute telephone interview, which was conducted using computer-assisted telephone interview technology. Patients were also asked to allow study staff to access electronic medical data from the time they enrolled in the health plan until 3 years after the date of the interview. Patients who completed the interview at GHC were mailed $20 cash reimbursement, whereas those at KPNC who completed the interview received a $50 gift card reimbursement. The differential incentive payments refl ected the researchers' prior experience with achieving acceptable response rates at their institutions.
Assessment of Misuse
Three different types of misuse were determined presumptively: non-pain symptoms (using opioids for stress or sleep), nonadherence (self-increasing dose or early refi lls), and aberrant behavior (giving opioids to or getting them from others). Two face-valid questions were used to evaluate each type of misuse. Misuse for non-pain symptoms was assessed by responses to these questions: (1) "In the past 2 weeks, how often did you use an opiate medicine to help calm your nerves or to give yourself a break from stress?" and (2) "In the past 2 weeks, how often did you take opiate medicine in order to help you sleep at night?" Nonadherence was classifi ed by answers to these questions: (1) "In the past 2 weeks, how often did you use more opiate medicine than your doctor prescribed in order to control your pain?" and (2) "In the past year, about how many times did you have to request an early refi ll because you ran out or because you lost or misplaced your opiate pain medicine?" Aberrant behavior was determined by responses to these questions: (1) "In the past year, about how many times did you give some of your opiate medicines to a relative or friend?" and (2) "In the past year, about how many times did a relative or friend give you some of their opiate medicine?" A patient was classifi ed as negative on a specifi c misuse type if she or he responded "never" to both items comprising the scale; otherwise, a patient was considered to be positive for that type of misuse.
Depression Measure
Depressive symptoms during the past 2 weeks were measured with the 8-item version of the Patient Health Questionnaire (PHQ-8), a validated self-report measure of depression. 28 The PHQ-8 is the same as PHQ-9 minus the question about suicidal ideation. PHQ-9 scoring cut-offs were used. Scores of 0 to 4 were classifi ed as not depressed, 5 to 9 as mild depression, 10 to 14 as moderate depression, and 15 and higher as severe depression.
Statistical Analyses
All reported analyses were weighted to adjust for the differences in sample selection probabilities by average daily dose as calculated from the electronic pharmacy data. SAS PROC SURVEYMEANS and PROC SUR-VEYREG software (SAS/STAT 9.2, SAS Institute Inc) was used to account for the stratifi ed random sampling approach, providing estimates for the population surveyed. Basic statistics were used to describe patients surveyed. Adjusted odds ratios were calculated for the relationship of depression (PHQ-8, 0 to 4 points [reference], 5 to 9 points, 10 to 14 points, and 15 points and higher) to the positive misuse score using categorical logistical regression. The covariates in the adjusted model included age, sex, education, race, marital status, average pain severity, 29 morphine-equivalent dose (1 to 49 mg, 50 to 99 mg, and 100 mg and higher), and survey site (GHC and KPNC). Pain severity was assessed by asking patients to rate their pain using a scale ranging from 0 to 10, in which 0 is "no pain" and 10 is "pain as bad as could be."
RESULTS

Survey Participation
At GHC, 2,185 patients were approached of whom 2,109 were considered eligible; among these eligible patients, 1,191 completed the interview. At KPNC, 1,605 persons were approached of whom 1,496 were considered eligible; among these eligible patients, 972 completed the interview. The total number of completed interviews was 2,163, for an overall response rate of 60% (57% at GHC and 65% at KPNC). The sample population examined here excluded patients with SUDs and those who had not used opioids in the past 2 weeks, which reduced the total completed interviews to 1,334 (776 from GHC and 558 from KPNC). Table 1 displays the demographic and clinical characteristics of the 1,334 survey respondents. Respondents were more frequently middle-aged, white, married, and female. Average pain severity ranged most frequently from 3 to 5. The majority had a PHQ-8 score of less than 10. Table 2 compares rates of positive misuse by demographic and clinical information. A higher percentage of misuse for non-pain symptoms and aberrant behavior was observed with lower daily dose and less education. Male sex and GHC site were also associated with higher percentages of misuse for non-pain symptoms. Increased pain severity was associated with nonadherence. Younger age was associated with nonadherence and aberrant behavior. Higher percentages of aberrant behavior were observed in whites. Table 3 displays the adjusted relationship between depression and other clinical characteristics with respect to misuse for non-pain symptoms. Patients with moderate and severe depressive symptoms were 1.75 (P = .031) and 2.42 (P =.001) times more likely, respectively, to misuse their opioid medications for non-pain symptoms than were patients who were not depressed. Table 4 displays the adjusted relationship between depression and other clinical factors in terms of nonadherence. Patients with mild, moderate, and severe depressive symptoms were 1.93 (P <.001), 2.89 (P <.001), and 3.13 (P <.001) times more likely, respectively, to use more opioids than prescribed compared with patients who were not depressed. Table 5 examines the adjusted relationship between depression and other clinical information with respect to aberrant behavior misuse. There was no statistically signifi cant association between depressive symptoms and giving opioids to or getting them from others. Figure 1 
Descriptive Results
Misuse, Depression, and Other Demographic and Clinical Characteristics
DISCUSSION Opioid Misuse and Depression
This study found that depression in the absence of substance abuse is signifi cantly associated with 2 forms of self-reported prescription opioid misuse as defi ned by (1) using opioids for stress or sleep and (2) using more opioids than prescribed. This relationship persisted after controlling for relevant demographic and clinical factors. A dose-response relationship was evident, with more severe depression showing a stronger association with these forms of misuse. No signifi cant association was noted between depression and giving opioids to or getting them from others. These results begin to clarify the types of opioid misuse associated with depression among patients without SUDs.
According to a recent review, estimates of the prevalence of opioid misuse among recipients of COT vary widely, from 3% to 62%. 30 This fi nding is likely a result of differences in source populations (many studies excluded mental health diagnoses and SUDs) and varying defi nitions of misuse. Previous research using urine toxicology screens have found prevalence rates of opioid misuse ranging from 20% to 40%. 31 Rates of misuse reported in our study varied depending on the type of misuse examined and the severity of depressive symptoms, which ranged from 12.3% to 57.7%. In our study, patients who were not depressed had lower rates of opioid misuse overall, peaking at 36.9% for non-pain symptoms. It is diffi cult to tease out a causal relationship between opioid misuse and depression. It is possible that opioid misuse produces depression, eg, by increasing apathy and lethargy. Alternatively, opioids are known to have independent anxiolytic and mood-altering properties that may prompt misuse in depressed patients. Historically, opioids have been used to treat psychological distress (mania and melancholia), as well as physical pain, 32, 33 and more recently studies have suggested using opioids for treatment-resistant depression and anxiety. [34] [35] [36] [37] It is also possible that depressed patients may experience their pain as more severe, which may prompt misuse. 38 A recent study of elderly adults supports the association of current depressive symptoms and opioid misuse. 39 Research has shown that patients with depression were more likely to initiate and continue opioid therapy than were patients who were not depressed. 18 In this article, we present evidence that patients with current depressive symptoms are more likely to take opioids for nonpain symptoms and to take extra medications. In contrast, behaviors that are arguably more aberrant, such as giving medications to or getting medications from others, may be limited to those with SUDs.
Opioid Misuse and Other Risk Factors
This study also sought to identify other risk factors for misuse. Risk factors for misuse for non-pain symptoms included male sex, lower average daily dose (which may be related to using more short-acting, as-needed opioids), less education, and being a member of GHC (which may be due to other socioeconomic factors). For nonadherence and aberrant behavior, younger age was identifi ed as a risk factor, which has been identifi ed previously. 19 Higher pain severity was also associated with increased nonadherence, which may refl ect undertreatment of pain in accord with the pseudoaddiction theory. 38, 39 White race, less education, and lower daily dose were associated with increased aberrant behavior.
Limitations
Our study has several limitations. The 2-item questions for each type of misuse described in this study a Scored on a scale in which 0-4 = no, 5-9 = mild, 10-14 = moderate, and ≥15 = severe depression.
b Scored on a scale ranging from 0-10 in which a higher score indicates worse pain.
were only a preliminary measure of opioid misuse; more extensive and internally consistent opioid misuse measures are needed. Our defi nition of opioid misuse was broad. A relatively high proportion of patients who were not depressed engaged in non-pain symptom misuse. This fi nding may be because sleep disturbance and stress are common in patients with chronic noncancer pain. Patients may regard using opioids to relieve these symptoms as a legitimate way to treat the effects of pain rather than as a form of misuse. It is possible that some patients with SUDs were misclassifi ed because our study relied on self-report and automated data. The response rates in this study, which were not optimal, may be partly because many patients on COT are functionally disabled, which is generally associated with lower response rates. Despite reassurance that no survey information would be communicated to health care clinicians, some respondents may have been concerned about jeopardizing their access to COT. Our estimated misuse associations may be conservative given the nature of self-reported data.
In conclusion, clinicians should be alert to the risk of patients with depressive symptoms using their opioids to relieve those symptoms. At this point, it is not clear whether opioids are substituting for, or even disrupting, the appropriate treatment of depression. Although patients and perhaps clinicians may think that relieving pain with opioid medications will also alleviate symptoms of depression, there is no evidence from controlled trials that opioids are adequate treatment for depression. Our study shows that unrelieved depressive symptoms increase risk for opioid misuse when defi ned as using opioids for stress or sleep and using more than prescribed. Clinicians should consider psychiatric consultation if depressive symptoms persist despite treatment. Several studies have found that severe chronic pain makes depression more treatment resistant. 40, 41 Our study suggests that if depressed patients are not in full remission, they remain at increased risk of opioid misuse. In light of the correlation between misuse and overdose, 3, 4 this population of depressed patients on COT is likely at even higher risk for overdose, either accidental or intentional. All these factors increase the necessity and the urgency of effective depression treatment in patients treated with COT. Future prospective and randomized studies should examine whether treatment of depression decreases the risk of opioid misuse. 
